The main factors boosting the growth of the global shoulder replacement market are - the rising number of surgeries, the technological advancements, increasing disposable income, increasing focus on cost efficiency, transparency of data, increased strategic alliances to initiate knowledge sharing, and the rising life expectancy of the population.
However, the market is not devoid of hurdles. Delayed tendering and reimbursement streamlining, poor operational environment, higher cost concerns, and increasing import duties on healthcare products could pose a threat to the growth of the global shoulder replacement market in the coming years.
The global shoulder replacement market is segmented on the basis of implant type, end user and region. With respect to implant type, it is further segmented into anatomical shoulder prosthesis and reverse shoulder prosthesis.
By end user, the market is segmented into hospitals, ambulatory surgical centers and orthopedic clinics. By region, the global shoulder replacement market is segmented into North America, Latin America, Europe, Asia Pacific (APAC), and Middle East and Africa (MEA).
The anatomical shoulder prosthesis segment is expected to dominate the global shoulder replacement market by implant type, and is anticipated to register a CAGR of 8.1% during the period of forecast; the segment will show dominance by reaching a market value of about USD 2bn.
By region, North America is expected to dominate the global shoulder replacement market by registering high growth throughout the period of forecast as compared to other regions. Following North America, Asia Pacific also shows higher potential and is set to witness a CAGR of 7.4% during the forecast period.
The hospitals segment is expected to dominate the global shoulder replacement market by end user to reflect a market value of more than USD 1.6bn by the end of 2025 and is poised to grow at the highest growth rate during the forecast period.
Following this segment, the ambulatory surgical centers segment also shows higher growth rate and is poised to register a CAGR of 7.8% during the forecast period.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government